Elite Pharmaceuticals (ELTP) Q1 2026 earnings summary

Executive summary

• Quarterly revenue reached $40.2 million, more than doubling year-over-year, driven by strong Elite label and Lisdexamfetamine sales, as well as new product launches like Oxycodone/Acetaminophen generics.

• Gross profit margin improved to 68% from 45% in the prior year, reflecting high-margin Lisdex sales and favorable product mix.

• Operating income for the quarter was $21.7 million, a 456%–462% increase over the prior year.

• Net loss of $5.9 million resulted from a $22.1 million non-cash expense related to warrant derivative liabilities, despite strong operating results.

• Working capital increased to $67.1 million, supported by higher inventory, accounts receivable, and cash balances.

Financial highlights

• Revenue for the quarter was $40.2 million, up 114% from the same quarter last year.

• Gross profit increased to $27.2 million, with gross margin rising to 68%.

• Operating income rose to $21.7 million, up from $3.9 million in the prior year.

• Net loss per share was $(0.01), mainly due to a $22.1 million non-cash derivative expense.

• Operating cash flow improved to $14.8 million, up from $3.1 million year-over-year.

Outlook and guidance

• Lisdex expected to remain a key growth driver, though margins will decline as the generic market matures and competition intensifies.

• The company is shifting focus from licensing to direct marketing of Elite label products for higher margins.

• Commercialization of new generics, including anticoagulant and pain management products, depends on FDA approval and patent outcomes.

• Continued focus on M&A as the preferred strategic path, with uplisting to Nasdaq as a secondary option if no suitable acquisition occurs by early 2026.

• Market share for Lisdex is about 8%, with further volume growth anticipated as generic conversion increases.